This Year In Medicine

2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.

New CDC recommendations on hepatitis B vaccination raise concerns over increased infections and healthcare costs, complicating public health efforts.

Clinicians across specialties explain how health misinformation is reshaping patient decisions, delaying care, and undermining trust.

Results of an exclusive Urology Times survey indicate heightened concern among older men about prostate cancer screening.

Innovative therapies and devices are transforming food allergy management, enhancing safety and quality of life for patients and families.

Discover how updated diagnostic criteria for multiple sclerosis enhance accuracy and confidence in clinical practice, utilizing advanced imaging and biomarkers.

Topical steroid withdrawal remains a controversial topic in the dermatology field, given the lack of necessary data.

Experts redefine obesity, distinguishing between preclinical and clinical forms, aiming to improve diagnosis and treatment strategies for better health outcomes.

GLP-1 medications are revolutionizing treatment for neurological conditions.

2025 data show the US is still failing to adequately identify and initiate care for deadly lung disease. Experts discuss what it will take to turn the tide on this public health issue.

Historic progress in renal xenotransplantation in 2025 brings pig kidney transplants closer to clinical reality amid an ongoing donor organ shortage.

Explore the evolving role of AI in dermatology, balancing its benefits with concerns over accuracy, bias, and the human touch in patient care.

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.

Explore the latest advancements in kidney stone treatment, focusing on suction technology and its impact on surgical outcomes and patient safety.

This special edition episode explores the advancements in incretin therapies that defined 2025.

Recent advancements in HAE treatments offer hope, but experts stress the need for more pediatric options and diverse therapies.

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

Discover how precision medicine reshapes COPD treatment, focusing on inflammation and patient-specific traits for improved outcomes in airway diseases.

Lungcast reflects on this year in pulmonology, looking back at such topics ranging from the American Lung Association ‘State of the Air’ report to artificial intelligence in lung imaging.

Neurokinin-3 receptor antagonists such as elinzanetant and fezolinetant provide non-hormonal options for managing hot flashes linked to menopause.

Resmetirom made history when it became the first and only FDA-approved MASH drug in 2024, but the pipeline continues to show promise heading into 2025.

In this episode of Crisis Point, this year’s news regarding benzene found in acne products is discussed by David Light, Neal Bhatia, MD, and Christopher Bunick, MD, PhD.

MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.

With new revisions of the MS diagnostic criteria being made, clinicians highlighted key updates and the broader implications it has for diagnosis, treatment, and healthcare practices worldwide.

Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and neffy.

Resistance is expected to worsen significantly, but can a combination of both ground-level clinician stewardship actions as well as systemic reforms such as the Pasteur Act at least slow down the train?